SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier (Q38081973)

28 August 2017

SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier (English)

1 reference

28 August 2017

1

Masaaki Kawano

1 reference

28 August 2017

Masanori Matsui

2

1 reference

PubMed ID

23414410

28 August 2017

Hiroshi Handa

series ordinal

3

1 reference

28 August 2017

1 February 2013

1 reference

Expert Review of Vaccines

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

199-210

1 reference

28 August 2017

2

1 reference

Prospects for a vaccine against the hepatitis C virus

28 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Advances in tuberculosis vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

The immune response during acute HIV-1 infection: clues for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Vaccine design for CD8 T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Rationalizing the development of live attenuated virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Learning vaccinology from viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Vaccine adjuvants: putting innate immunity to work

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Immunological mechanisms of vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Immunologic basis of vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Nonreplicating vaccinia vector efficiently expresses recombinant genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Virus-like particles as a vaccine delivery system: myths and facts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Structure of simian virus 40 at 3.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

The structure of simian virus 40 refined at 3.1 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Interaction of polyomavirus internal protein VP2 with the major capsid protein VP1 and implications for participation of VP2 in viral entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

SV40 VP2 and VP3 insertion into ER membranes is controlled by the capsid protein VP1: implications for DNA translocation out of the ER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Self-assembly of purified polyomavirus capsid protein VP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Polymorphism in the assembly of polyomavirus capsid protein VP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Presentation of functional foreign peptides on the surface of SV40 virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Evidence that SV40 VP1-DNA interactions contribute to the assembly of 40-nm spherical viral particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

In vitro reconstitution of SV40 particles that are composed of VP1/2/3 capsid proteins and nucleosomal DNA and direct efficient gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Primary human cervical carcinoma cells require human papillomavirus E6 and E7 expression for ongoing proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cell and molecular biology of simian virus 40: implications for human infections and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Simian virus 40 transformation, malignant mesothelioma and brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Efficient introduction of plasmid DNA into human hemopoietic cells by encapsidation in simian virus 40 pseudovirions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Site-directed mutation affecting polyomavirus capsid self-assembly in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Chaperone-mediated in vitro assembly of Polyomavirus capsids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Chaperone-mediated in vitro disassembly of polyoma- and papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Possible role for cellular karyopherins in regulating polyomavirus and papillomavirus capsid assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

In vitro assembly of SV40 virions and pseudovirions: vector development for gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

In vitro-packaged SV40 pseudovirions as highly efficient vectors for gene transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Simian virus 40 VP1 capsid protein forms polymorphic assemblies in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Caveolar endocytosis of simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Simian Virus 40 depends on ER protein folding and quality control factors for entry into host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

The VP2/VP3 minor capsid protein of simian virus 40 promotes the in vitro assembly of the major capsid protein VP1 into particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Calcium bridge triggers capsid disassembly in the cell entry process of simian virus 40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Importance of calcium-binding site 2 in simian virus 40 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Importance of Vp1 calcium-binding residues in assembly, cell entry, and nuclear entry of simian virus 40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Simian virus 40 Vp1 DNA-binding domain is functionally separable from the overlapping nuclear localization signal and is required for effective virion formation and full viability

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Inside polyomavirus at 25-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

High cooperativity of the SV40 major capsid protein VP1 in virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Polyomavirus EGFP-pseudocapsids: analysis of model particles for introduction of proteins and peptides into mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Efficient intracellular delivery of a protein and a low molecular weight substance via recombinant polyomavirus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Coupling of antibodies via protein Z on modified polyoma virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Formation of polyomavirus-like particles with different VP1 molecules that bind the urokinase plasminogen activator receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Structure of murine polyomavirus complexed with an oligosaccharide receptor fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Gangliosides are receptors for murine polyoma virus and SV40

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Identification of gangliosides GD1b and GT1b as receptors for BK virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Ganglioside GT1b is a putative host cell receptor for the Merkel cell polyomavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Mutations in the GM1 binding site of simian virus 40 VP1 alter receptor usage and cell tropism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cell selective targeting of a simian virus 40 virus-like particle conjugated to epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Antigen recognition by class I-restricted T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Peptides naturally presented by MHC class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Mechanisms of MHC class I--restricted antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Degradation of cell proteins and the generation of MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Technologies for enhanced efficacy of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Developments in virus-like particle-based vaccines for infectious diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

The mechanism of action of MF59 - an innately attractive adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

How do adjuvants work? Important considerations for new generation adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Regulation of adaptive immunity by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Engineered lentivector targeting of dendritic cells for in vivo immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Virus-like particle based vaccines for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Identification of a neutralization epitope in the VP1 capsid protein of SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

Uncatalyzed assembly of spherical particles from SV40 VP1 pentamers and linear dsDNA incorporates both low and high cooperativity elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

GM1 structure determines SV40-induced membrane invagination and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.149

21 January 2018

Identifiers

DOI

10.1586/ERV.12.149

1 reference

28 August 2017

1 reference

PubMed ID

23414410